Jasper Therapeutics Inc (JSPR)

Jasper Therapeutics Inc (JSPR) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $19M; returns 1 day +2.9%, 1 week +6.3%, 1 year -78.1%.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing Briquilimab, a novel antibody therapy for chronic mast cell diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.

Groups JSPR belongs to

• Clinical Stage Biotech
• Biotechnology
• Clinical Stage
• Monoclonal Antibodies
• Healthcare
• Life Sciences
• Antibody Therapeutics
• Autoimmune Diseases
• Rare Diseases

JSPR financial model: income statement, cash flow and balance sheet